Benefits of ultrasound contrast agents may outweigh risks

June 2008
Cardiology Today;Jun2008, Vol. 11 Issue 6, p44
The article reports that researchers at Saint Louis University in Missouri, led by Doctor Melda Dolan, associate professor of cardiology, called on the U.S. Food and Drug Administration (FDA) to reconsider a black box warning label it placed on an ultrasound contrast agent in late 2007. Research conducted by Dolan and colleagues, however, determined the contrast agent to be safe and pointed out that the benefits of the treatment outweigh the risks.


Related Articles

  • Risk Management Policy and Black-Box Warnings. Cook, Daniel M.; Gurugubelli, Rama K.; Bero, Lisa A. // Drug Safety;2009, Vol. 32 Issue 11, p1057 

    Background: The US FDA increasingly applies risk management to drug safety policy. Little is known about the process by which the FDA approves labelling changes. Although advisory committees can recommend any of the risk management tools, including the use of 'black-box warnings', it is unknown...

  • Improving the Food and Drug Administration's Mandate to Ensure Postmarketing Drug Safety. Qato, Dima M.; Alexander, G. Caleb // JAMA: Journal of the American Medical Association;10/12/2011, Vol. 306 Issue 14, p1595 

    The author offers insight on efforts by the U.S. Food and Drug Admdinistration (FDA) to improve its mandate to ensure the post-marketing drug safety. The author cites several reasons for concern about the new system of Risk Evaluation and Mitigation Strategies (REMS) implemented by the FDA. The...

  • Specialty pharmacy's role in REMS, FDA's new drug safety program. Russek, Steven B. // Formulary;Oct2009, Vol. 44 Issue 10, p300 

    Prescription drug safety is a topic that generates a great deal of attention in the headlines, among patient communities, and in the US civil court system. A problem arises when a drug offers significant therapeutic benefits but also carries challenging health or safety risks. FDA recently...

  • Revising REMS: FDA is looking to streamline processes for ensuring safe and appropriate use of high-risk drugs. Wechsler, Jill // Pharmaceutical Executive;Sep2010, Vol. 30 Issue 9, p14 

    The article focuses on the insights of healthcare providers on the effectiveness of the U.S. Food and Drug Administration's (FDA) program for establishing Risk Evaluation and Mitigation Strategies (REMS) designed to oversee safety of high-risk drugs. It notes that physicians, pharmacists as well...

  • Bisphenol A assessment relied on 'useless' studies.  // ENDS (Environmental Data Services);Nov2008, Issue 406, p29 

    The article looks at several issues surrounding a study, which assessed the risk associated with the plastics intermediate bisphenol A. The study that was carried out by the European Food Safety Authority (EFSA) and the U.S. Food and Drugs Administration (FDA) was condemned by a group of 36...

  • "New Studies Show Ultrasound Contrast Agents Are Safe," ICUS Tells FDA Panel.  // Biomedical Market Newsletter;5/9/2011, p664 

    The article offers information on the new studies conducted by International Contrast Ultrasound Society (ICUS) which revealed that ultrasound contrast agents are safe and useful diagnostic tools. It mentions that ICUS informed the advisory panel of U.S. Food and Drug Administration (FDA) that...

  • ICUS Pleased by FDA Modification of Boxed Warnings on Additional Ultrasound Contrast Agents.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article offers information that the International Contrast Ultrasound Society (ICUS) admired the decision of the U.S. Food & Drug Administration (FDA) to modify the U.S. product label for Optison, an ultrasound contrast agent. The label change was supported by a Citizen Petition filed by...

  • Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database. Hauben, Manfred; Hung, Eric; Hanretta, Kelly; Bangalore, Sripal; Snow, Vincenza; Hung, Eric Y; Hanretta, Kelly C // Drug Safety;Nov2015, Vol. 38 Issue 11, p1127 

    Introduction: Perflutren microbubble/microsphere ultrasound contrast agents have a black-box warning based on case reports of serious cardiopulmonary events. There have been several subsequent observational safety studies. Large spontaneous reporting databases may help detect/refine...

  • ICUS Pleased by FDA Modification of Boxed Warnings on Additional Ultrasound Contrast Agents.  // Biomedical Market Newsletter;8/22/2012, Vol. 21, p1 

    The article reports that the International Contrast Ultrasound Society (ICUS) has applauded the U.S. Food & Drug Administration's (FDA's) decision to modify the U.S. product label for OPTISON. OPTISON is an ultrasound contrast agent which is used to improve the accuracy of radiation-free...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics